Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 13, 2008 09:00 ET

Ambrilia to Present at BIO2008

MONTREAL, QUEBEC--(Marketwire - June 13, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at the BIO2008 International Convention to be held in San Diego, June 17-20. This presentation will take place on Thursday, June 19, at 10:30 am local time, in Room 5B.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site:

Contact Information